INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ultragenyx Pharmaceutical Inc. of Class Action Lawsuit and Upcoming Deadlines – RARE

Core Viewpoint - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices, with investors encouraged to join the lawsuit [1][2]. Group 1: Lawsuit Details - The class action lawsuit concerns whether Ultragenyx and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors have until April 6, 2026, to request to be appointed as Lead Plaintiff if they purchased Ultragenyx securities during the Class Period [2]. Group 2: Stock Performance and Events - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4]. - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to achieve statistical significance, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5].